Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Thursday, Zacks reports.
Separately, Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Strong Buy”.
Read Our Latest Report on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Stock Up 1.0%
SGIOY traded up $0.09 on Thursday, reaching $9.22. The company’s stock had a trading volume of 163,940 shares, compared to its average volume of 95,038. The company has a market capitalization of $15.69 billion, a price-to-earnings ratio of 9.22, a P/E/G ratio of 3.27 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR has a fifty-two week low of $7.83 and a fifty-two week high of $12.00. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $9.07 and a two-hundred day moving average of $9.27.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. As a group, analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current fiscal year.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.
Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.
Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.
Further Reading
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
